目的 探討依達拉奉右莰醇聯(lián)合腦蛋白水解物治療急性腦梗死的臨床療效。方法 選取2021年10月-2022年10月唐山市工人醫(yī)院收治的84例急性腦梗死患者,按照隨機數(shù)字表法分為對照組和治療組,每組各42例。對照組患者靜脈滴注予腦蛋白水解物注射液,取250 mL生理鹽水,加入腦蛋白水解物注射液10 mL,1次/d;治療組在對照組基礎(chǔ)上靜脈滴注依達拉奉右莰醇注射用濃溶液,15 mL加入100 mL生理鹽水,2次/d。兩組均連續(xù)用藥2周。觀察兩組的臨床療效,比較兩組治療前后美國國立衛(wèi)生研究院卒中量表(NIHSS)評分、神經(jīng)生長因子(NGF)、基質(zhì)金屬蛋白酶-9(MMP-9)及N-末端腦鈉肽前體(NT-proBNP)的變化情況。結(jié)果 治療后,治療組總有效率是92.86%,顯著高于對照組的71.73%(P<0.05)。治療1、2周兩組NIHSS評分均較治療前有所下降(P<0.05),且治療組下降程度更明顯(P<0.05)。治療后,兩組血清NGF較治療前顯著上升,MMP-9、NT-proBNP水平均較治療前下降(P<0.05),且治療組血清細胞因子水平改善更顯著(P<0.05)。結(jié)論 依達拉奉右莰醇聯(lián)合注射用腦蛋白水解物治療急性腦梗死的療效顯著,能有效促進患者神經(jīng)功能恢復(fù),可以提高血清NGF,降低MMP-9及NT-proBNP水平,且安全性可靠,值得臨床推廣使用。

Objective To investigate the effect of edaravone and dexborneol combined with cerebroprotein hydrolysate in treatment of acute cerebral infarction. Methods A total of 84 patients with acute cerebral infarction admitted to Tangshan Workers' Hospital from October 2021 to October 2022 were selected and divided into control group and treatment group according to random number table method, with 42 patients in each group. Patients in the control group were iv administered with Cerebroprotein Hydrolysate Injection, 10 mL was added into 250 mL normal saline, once daily. Patients in the treatment group were iv administered with Edaravone and Dexborneol Concentrated Solution for injection on the basis of the control group, 15 mL was added into 100 mL normal saline, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of National Institutes of Health Stroke Scale (NIHSS) score, nerve growth factor (NGF), matrix metalloproteinase-9 (MMP-9) and N-terminal brain natriuretic peptide precursor (NT-proBNP) were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 92.86%, significantly higher than that of the control group (71.73%) (P < 0.05). After 1 week and 2 weeks of treatment, the NIHSS scores in both groups were decreased compared with those before treatment (P < 0.05), and the decrease in the treatment group was more significant (P < 0.05). After treatment, serum NGF of the two groups was significantly increased compared with that before treatment, but the levels of MMP-9 and NT-proBNP were decreased compared with that before treatment (P < 0.05), and the serum cytokine levels in the treatment group were more significantly improved (P < 0.05). Conclusion Edaravone and dexborneol combined with cerebroprotein hydrolysate has remarkable curative effect in treatment of acute cerebral infarction, and can effectively promote the recovery of neurological function in patients, and can improve serum NGF, reduce the level of MMP-9 and NT-proBNP with safe and reliable, which is worthy of clinical promotion and use.

R971